MEDIA & PUBLICATION
MEDIA & PUBLICATION
Events & Presentation
Lin BioScience: Corporate Overview
Lin BioScience Inc.(TPEx: 6696) is a drug development company specializing in innovative therapies for diseases with unmet medical needs. Our diverse and novel pipeline consists of first-in-class drugs aimed at treating life-threatening or disabling diseases in oncology, ophthalmology and metabolic disease.
Lin BioScience is led by a management team with experienced background and talents in new drug development to research and develop breakthrough therapeutics and provide promises to patients who suffer from severe diseases.
MBA MMed PhD(Med)
Chairman & CEO
Dr. Tom Lin graduated from The University of Sydney Medical School with a multi-disciplinary specialization in cardiology, neurology, immunology, and was awarded a PhD in Medicine for his research and development of immunotherapies in the treatment of autoimmune neuropathies. During his doctoral training, Dr. Lin was also awarded a fellowship at The University of Melbourne, where he completed his Specialist Certificate in Clinical Neuroscience, and trained under visiting professor, Dr. Barry Marshall (Nobel Laureate in Medicine) in clinical research and drug development.
Dr. Lin’s educational background also includes Clinical Scholars Program from Harvard Medical School and The Royal college of Physicians (London), and an Executive MBA and Global Chief Executive Program from Columbia University, London Business School, and Wharton Business School. Prior to founding Lin Bioscience, Dr. Lin has served as President, Chief Operations Officer, and Medical Director for biotech and pharmaceutical companies. Dr. Lin has a vast clinical and drug development experience in cardiovascular, oncology, immuno-oncology, autoimmune and anti-inflammatory therapeutic areas, and has a successful track record in taking biotech start-up companies to IPO.
Dr. Wang joined Lin BioScience as a founding employee in 2016 as Director of R&D and Business Development. She is experienced in discovery, preclinical and early clinical development. Over her career, Dr. Wang has led discovery programs that advanced investigational medicines into clinical development in a wide range of therapeutic areas, including oncology and cardiovascular diseases. Dr. Wang received a Bachelor of Science in Chemistry, Ph.D. in Biological Sciences from National Taiwan University, and her MBA degree in University of California, San Diego. She was a postdoctoral fellow at Scripps Research Institute.
Prior to joining Lin BioScience, Dr. Wang served as Director of Research & Development for biotechnology start-ups. Dr. Wang has demonstrated her leadership in CMC, Preclinical & Pharma/tox, Companion Diagnostics, Clinical & Bioassays and global Phase 2 Clinical Development & Regulatory submissions.
Miss Chen is a certified pharmacist and holds a master’s degree in Science (Medicinal Chemistry). Miss Chen has vast experience in clinical trial management and regulatory submissions with over 50 studies in various indications, ranging from Phase 1 to global Phase 3 studies. Prior to joining Lin BioScience, Miss Chen served as Global Project Lead, Project Manager, Clinical Operations Manager, Clinical Quality Manager and Clinical Research Associate in Pfizer Taiwan and biotechnology companies.
MBA CFA FRM
Mr. Chuang is a Charted Financial Analyst and a certified Financial Risk Manager. He graduated from The National Taiwan University with Bachelors in Economics and Business Administration, and a joint Global Executive MBA from The University of Hong Kong, London Business School, and Columbia University.
Prior to joining Lin BioScience, Mr. Chuang has served on several executive and director positions for leading Chinese multinational corporations, where he has led several high-profile IPOs, investments and acquisitions, which includes the acquisition of Inter Milan (Italian Series A-League Football Club) for Suning Group, led outbound direct investments for The People’s Insurance Company of China Asset Management, completed multi-billion-dollar multinational properties acquisitions for Wanda Group, and served as financial advisor for Agricultural Bank of China’s IPO (world’s second largest IPO) at CITIC Securities International.